Compare IAC/Interactivecorp (PPLI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs State Street SPDR S&P Biotech ETF — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.05B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.3× IAC/Interactivecorp's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PPLI | XBI | |
|---|---|---|
Market Cap | $3.05B | $10.11B |
Volume | 931,019 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $47.62 | $169.55 |
52-Week Low | $31.52 | $104.99 |
Typical Hold Time | 79 Days | 37 Days |
Enterprise Value | $3.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.
The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
